Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 immune stimulator-antibody conjugate NJH395

An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2 ISAC NJH395
Code name:NJH 395
NJH-395
NJH395
NJH395
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search